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ABSTRACT
Alternatively spliced Tissue Factor (asTF) is a secreted form of Tissue Factor (TF), 
the trigger of blood coagulation whose expression levels are heightened in several 
forms of solid cancer, including pancreatic ductal adenocarcinoma (PDAC). asTF 
binds to β1 integrins on PDAC cells, whereby it promotes tumor growth, metastatic 
spread, and monocyte recruitment to the stroma. In this study, we determined if 
targeting asTF in PDAC would significantly impact tumor progression. We here report 
that a novel inhibitory anti-asTF monoclonal antibody curtails experimental PDAC 
progression. Moreover, we show that tumor-derived asTF is able to promote PDAC 
primary growth and spread during early as well as later stages of the disease. This 
raises the likelihood that asTF may comprise a viable target in early- and late-stage 
PDAC. In addition, we show that TF expressed by host cells plays a significant role in 
PDAC spread. Together, our data demonstrate that targeting asTF in PDAC is a novel 
strategy to stem PDAC progression and spread.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) survival 
rate remains dismal, with 5-year survival < 5%, and 
by 2030 is predicted to be the third leading cause of 
cancer-related death [1]. Pancreatic cancer is commonly 
associated with thrombotic events, which contribute to its 
morbidity and mortality [2, 3]. Cancer coagulopathy is 
thought to be partially due to the up-regulation of Tissue 
Factor (TF), the primary initiator of blood clotting [4]
[5]. Multiple oncogenic events that are characteristic of 
PDAC, e.g. activation of the proto-oncogene K-RAS and 
inactivation/loss of p53 and PTEN, promote TF expression 
[6]. Recently, we reported that the secreted isoform of 
TF, termed alternatively spliced TF (asTF), is expressed 
in early-stage PDAC lesions (pancreatic intraepithelial 
neoplasia, PanIN) and abundant in advanced PDAC, 
in contrast to normal pancreas [7]. Our groups recently 
demonstrated that asTF acts on cancer cells in an auto/
paracrine manner via β1 integrins, promoting disease 
progression by fueling cancer cell proliferation, survival, 
metastatic spread, neovascularization, and monocyte 
accumulation in the tumor stroma [7, 8].
Unlike the much-studied major form of TF termed 
full-length TF (flTF), asTF is minimally coagulant, and 
triggers intracellular signaling through non-proteolytic 
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mechanisms by binding to α6β1 and αvβ3 integrins, and 
thereby activating PI3K/Akt, MAPK, and FAK pathways 
[9]. Integrin subunits α6 and β1 are up-regulated in PDAC, 
and play a crucial role in promoting PDAC progression 
[10]. asTF-β1 integrin interaction on microvascular 
endothelial cells increases the expression of cell adhesion 
molecules VCAM-1, ICAM-1, and E-selectin, which 
facilitates monocyte recruitment; we note that this effect 
is exerted by human and murine asTF [11, 12]. Levels 
of asTF positively correlate with the number of tumor 
associated monocytes/macrophages (TAMs), which are 
known to significantly contribute to tumor progression 
and resistance to chemotherapy [7–13]. Tumor cell-
derived asTF fuels PDAC primary growth and spread via 
upregulation of various signaling pathways [7]; however, 
it is not known whether host-derived TF also plays a 
discernible role in PDAC pathobiology. In addition, it is 
not known whether tumor cell- and/or host-derived asTF 
can be targeted with an asTF-specific monoclonal antibody 
to stem PDAC progression. 
In this study, we i) examined the asTF-integrin nexus 
as a potential therapeutic target in PDAC, including the 
activity of our novel, asTF-specific neutralizing antibody 
RabMab1; ii) delineated the mechanisms underlying asTF-
induced PDAC progression; and iii) elucidated the relative 
significance of host-derived TF in PDAC. We employed 
a doxycycline (Dox)-inducible asTF transgene system to 
rule out the possibility of cell line and/or clonal selection 
variability influencing experimental outcomes. Using 
this approach, we investigated whether delayed-onset 
upregulation of asTF yields a phenotype that is distinct 
from that obtained via constitutive overexpression. The 
effectiveness of antibody-based targeting of asTF in PDAC 
was assessed in vivo using an orthotopic mouse model.
RESULTS 
asTF-integrin interactions promote PDAC cell 
migration
We recently reported that constitutive asTF 
overexpression in human pancreatic cancer cells (Pt45.P1) 
promotes metastatic spread in vivo [7]; here we sought to 
investigate the mechanisms responsible and specifically 
whether asTF increases cell motility. We engineered Pt45.
P1 cells to inducibly express asTF (Pt45.P1/asTFi); when 
treated with Dox, Pt45.P1/asTFi cells had significantly 
higher levels of asTF mRNA and protein, while flTF 
mRNA and protein levels remained unchanged (p < 0.001) 
(Figure 1A, 1B). A scratch assay showed that Dox-treated 
Pt45.P1/asTFi cells had completed gap closure by 24 
hours, whereas untreated cells still had unoccupied area 
at 48 hours (Figure 1C). Because asTF- α6/β1 integrin 
interactions promote breast cancer cell proliferation [8], we 
sought to determine whether this enhanced scratch closure 
was mainly due to enhancement of PDAC cell migration 
rather than cell proliferation; thus, we performed a 5-hour 
cell migration assay under a serum chemo-gradient using 
laminin-coated transmembrane inserts and Pt45.P1/asTFi 
cells. Laminin is abundantly expressed in PDAC stroma 
and is known to bind α6β1 integrins [10, 14]. As in the 
scratch assay, Dox-treated cells exhibited a significantly 
higher migration rate compared to untreated cells. Notably, 
when untreated Pt45.P1/asTFi cells were pre-incubated 
with the inhibitory anti-asTF antibody RabMab1, their 
basal migration rate was significantly reduced (Figure 1D), 
indicating that even the relatively low basal levels of asTF 
constitutively expressed in Pt45.P1/asTFi cells significantly 
contribute to their migratory potential. Pre-incubating 
Pt45.P1/asTFi Dox+ with anti-α6 inhibitory antibody 
yielded a partial reduction of cell migration, whereas pre-
incubation with anti-β1 or anti-β1/anti-α6 fully inhibited 
cell migration (Figure 1D). Thus, asTF expressed in PDAC 
cells facilitates their integrin-mediated motility, a hallmark 
of PDAC progression and metastasis.
asTF promotes primary growth and spread 
in vivo at early and later stages of tumor 
development
To examine the temporal effect of asTF 
overexpression on tumor progression in vivo, we 
orthotopically implanted 1 × 106 Pt45.P1/asTFi cells into 
the pancreata of nude mice (n = 5/group) and allowed 
tumors to develop for 5 weeks. Mice received Dox (2 
µg/mL) in sucrose drinking water at day 1 (“Dox”), 
day 25 (“Late Dox”), or sucrose alone (“No Dox”), and 
tumor progression was monitored in vivo using CVM-
SapC[H2]-DOPS imaging (Figure 2A). At 2.5 weeks 
post-implantation, no differences in tumor take and/
or metastatic spread were observed between the cohorts 
(data not shown). At the end of the experiment, tumor 
growth was observed in all mice except one animal in 
the “Late-Dox” cohort. No appreciable distal metastases 
were observed in the “No Dox” cohort compared to the 
other two cohorts; distal spread was significantly reduced 
in “Late Dox” mice compared to “Dox” mice (p = 0.010), 
yet it was in-trend higher in “Late Dox” mice compared to 
“No Dox” mice (p = 0.082) (Figure 2A, 2H). Mice were 
then euthanized and primary tumors resected and examined 
for weight and volume. “Dox” tumors were significantly 
larger in both mass and volume compared to “Late Dox” 
and “No Dox” tumors (Figure 2B, 2C). These observations 
indicate that elevated expression of asTF can promote 
PDAC progression during early as well as late stages of 
the disease, yielding larger tumors and increased spread. 
Upregulation of asTF expression alters the 
composition of tumor stroma
Next, we compared the histology of “No Dox”, 
“Late Dox”, and “Dox” Pt45.P1/asTFi tumors for vessel 
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density (CD31) and the levels of stromal M2-polarized 
tumor associated macrophages (TAMs) (CD206). While 
both “Late Dox” and “Dox” tumors had significantly 
increased vessel density compared to “No Dox” tumors, 
vessel density of “Late Dox” tumors was comparable 
to that of “Dox” tumors, which suggests that asTF-
potentiated PDAC vascularization plateaus relatively early 
(Figure 2D). “No Dox” tumors also had significantly fewer 
TAMs, as did “Late Dox” tumors when compared to “Dox” 
tumors (Figure 2E). Consistent with our in vitro results 
obtained with Pt45.P1/asTFi cells, immunohistochemical 
analysis of tumor tissue revealed an appreciable increase 
of asTF expression in “Dox” vs “No Dox” tumors; 
extensive co-localization of asTF and β1-integrin was 
observed (Figure 2F). Remarkably, asTF protein was 
present in the circulation of mice in “Late Dox” as well as 
“Dox” cohorts at levels exceeding 1 ng/mL (Figure 2G). 
Lastly, we analyzed the tumors for the levels of collagen 
deposition (Masson’s trichrome): “Late Dox” and “Dox” 
tumors had comparable collagen deposition, which was 
significantly higher compared to that in “No Dox” tumors 
(Figure 2I and 2J). Cumulatively, these findings suggest 
that asTF plays a multifaceted role in tumor stroma 
development, whereby it increases the levels of TAMs, 
vessel density, and collagen deposition.  
Targeting asTF impedes PDAC progression
To assess whether exposure to RabMab1 can 
stem the growth of PDAC cells expressing native levels 
of asTF in the orthotopic setting, as we found to be the 
case for breast cancer cells [8], we co-implanted Pt45.
P1 cells with RabMab1 or isotype control IgG using 
the same cell number and RabMab1 quantity that we 
previously employed in our breast cancer studies, i.e. 
100 µg/6 × 105 cells, and tumor growth was monitored 
periodically using CVM-SapC[H2]-DOPS in vivo imaging 
over 7 weeks (n = 8/cohort) (Figure 3A). Tumors co-
implanted with RabMab1 had a lower take compared 
to other cohorts (RabMab1: 4/8; IgG: 6/8; PBS: 7/8). 
Like PT45.P1/asTFi cells grown in mice not receiving 
Dox, Pt45.P1 cells did not exhibit significant spread 
even when grown for 7 weeks; when co-implanted with 
RabMab1, Pt45.P1 cells produced much smaller tumors 
(p < 0.001) (Figure 3B, 3C). Tumors produced by 
RabMab1-treated Pt45.P1 cells were also significantly less 
vascularized and had ~3.5 fold fewer M2 polarized TAMs 
compared to the tumors produced by Pt45.P1 cells co-
implanted with vehicle (PBS) and/or isotype control IgG 
(Figure 3D, 3E). Mice in the Pt45.P1/RabMab1 cohort 
had a ~2 fold decrease in the levels of circulating asTF 
Figure 1: TF isoform expression in Pt45.P1/asTFi cells. (A) asTF/flTF mRNA expression levels were assessed by quantitative 
real-time RT-PCR (n = 3). (B) Western blot, flTF/asTF protein levels in Pt45.P1 and Pt45.P1/asTFi cells; lysates were assessed for total 
protein concentration and volumes were adjusted accordingly. (C) Quantification of gap closure/scratch assay, Pt45.P1/asTFi cells treated 
and untreated with Dox. Bars depict the area unoccupied by Pt45.P1/asTFi cells (n = 3) at 0, 18, 24, and 48 hours. (D) Pt45.P1/asTFi cell 
migration toward serum in a transwell assay: laminin-coated transwell inserts were seeded with Pt45.P1/asTFi cells treated as indicated 
(n = 3 transwells per treatment; RabMab1 = mAb).
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compared to mice in the Pt45.P1/PBS and/or isotype 
IgG cohorts (Figure 3F, 0.27 ng/mL vs 0.60/0.54 ng/
mL, respectively; p < 0.001). Collagen deposition in the 
tumor stroma was also significantly reduced by RabMab1 
(Figure 3G, 3H). Thus, antibody-based targeting of asTF 
is likely to comprise a viable therapeutic strategy to stem 
PDAC progression.
Host TF contributes to PDAC progression
We next sought to evaluate the contribution of host 
TF to PDAC growth and spread in our model using TF- Het 
(control) and TF-Low SCID mice. TF-Low mice express 
low levels of flTF but no asTF [15, 16]; thus, phenotypic 
changes observed in TF-Low mice can be due to either a 
reduction in host flTF and/or a reduction in host asTF. In 
light of our findings in nude mice pointing to a limited 
spread of Pt45.P1 cells in the setting of 1 × 106 cells 
grown for 5 weeks (Figure 2) and/or 6 × 105 cells grown 
for 7 weeks (Figure 3), we attempted to facilitate systemic 
spread in this experiment by orthotopically implanting 
1 × 106 Pt45.P1 cells into TF-Low/Het mice and allowing 
tumors to develop over 7 weeks. In agreement with prior 
studies pointing to SCID mice as a better platform to study 
the metastatic capacity of human tumor cells compared to 
nude mice [17], we indeed observed significant spread of 
Figure 2: Growth of orthotopically implanted Pt45.P1/asTFi cells in nude mice. (A) Mice began receiving Dox (2 μg/mL) 
in sucrose at day 1 of the study (“Dox”), day 25 of the study (“late Dox”), or sucrose alone (“No Dox”), and tumor progression imaged 
by CVM-SapC-DOPS 5 weeks post-surgery (n = 5/cohort; top row, representative images). Bottom row: abdominal cavities of nude mice 
bearing orthotopic Pt45.P1/asTFi tumors. White arrow: normal pancreas; green outlines: tumor. Quantification of tumor mass (B) and 
tumor volume (C) in the three groups (n ≥ 4). (D) 8 view fields per specimen (n = 5 per specimen type) were counted and averaged for 
vessel density as assessed by anti-CD31 staining. (E) Levels of M2 polarized TAMs in the stroma. (F) Expression and co-localization of 
β1 integrin and asTF in tumors formed by Pt45P1/asTFi cells (scale bar = 20 μm). (G) Plasma from mice bearing Pt45.P1/asTFi tumors 
was assayed for asTF using ELISA (n = 5). (H) Quantification of tumor spread to distal sites in anesthetized mice via CVM-SapC-DOPS 
imaging (analyzed areas were above and below the orange lines). (I) Representative images, Masson’s Trichrome stain (scale bar = 50 μm). 
(J) Quantification of percent area positive for Masson’s Trichrome stain, 5 view fields per specimen (n = 5).
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Pt45.P1 cells in TF-Het mice (Figure 4A, 4D). The fraction 
of mice with detectable lung metastasis was higher in 
TF-Het mice than in TF-Low mice (4/6 vs 1/6). Pt45.P1 
tumors grown in TF-Low/Het mice were comparable 
in mass and volume (Figure 4B, 4C); however, tumor 
spread was significantly diminished in TF-Low mice 
(p = 0.007) (Figure 4A, 4D). Tumors in TF-Low mice also 
had lower vessel density (p = 0.033) and had fewer M2 
polarized TAMs in the stroma (p = 0.011) (Figure 4E, 4F). 
Fibrin(ogen) levels in the normal pancreata of TF-Het 
mice were comparable to those in TF-Low mice; in 
the tumors grown in TF-Het as well as TF-Low mice, 
fibrin(ogen) staining was prominent at the invasive edge/
capsule and in necrotic cores (Supplementary Material), 
which is in agreement with prior observations reported 
for lung lesions [18]. Notably, TF-Low tumors had 
decreased collagen deposition compared to TF-Het tumors 
(p = 0.018) (Figure 4G,  4H). These results indicate that 
host-derived TF likely contributes to PDAC spread. 
RabMab1 suppresses tumor growth equally well 
in TF-Het and TF-Low mice
To compare the relative contribution of tumor-
derived asTF and host flTF/asTF to tumor progression 
in our model, we analyzed the growth of Pt45.P1 cells 
co- implanted with RabMab1 or isotype control IgG in 
TF- Low and TF-Het mice. In the presence of RabMab1, 
Pt45.P1 cells implanted in TF-Low as well as TF-Het mice 
grew tumors that were significantly smaller compared 
to control tumors (Figure 5A, 5B). When grown in 
TF- Het mice, RabMab1 treated tumors had significantly 
Figure 3: Effects of RabMab1 on the growth of orthotopically implanted Pt45.P1 cells in nude mice. (A) Tumor 
progression was monitored in vivo via CVM-SapC-DOPS imaging over 7 weeks (n ≥ 3). (B) Quantification of primary tumor mass (n ≥ 3). 
(C) Representative specimens, resected tumors. (D) Eight view fields per specimen (n = 3 per specimen type) were assessed for vessel density, 
and (E) for M2 polarized TAMs. (F) Plasma samples from each cohort bearing Pt45.P1 tumors were assayed for asTF using ELISA (n = 3). 
(G) Representative images, Masson’s Trichrome stain (scale bar = 50 μm). (H) Quantification of percent area positive for Masson’s 
Trichrome stain. (RabMab1 = mAb).
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more TUNEL positive nuclei (p = 0.0475); there was 
no difference in the percent of TUNEL positive nuclei 
in the tumors grown in TF-Het and TF-Low mice (data 
not shown). We previously reported that constitutive 
overexpression of asTF in PT45.P1 cells induces MAPK 
and Akt phosphorylation [7]; in this study, MAPK p42/44 
phosphorylation levels were unaffected by RabMab1 
treatment (data not shown), yet a highly significant 
decrease in pAKT-T308 was observed (p = 0.002), while 
the levels of pAKT-S473 were unaffected (Figure 5C). 
RabMab1 reduced the percent of Ki67+ positive nuclei 
and tumor vascularization equally well in TF-Het and TF-
Low mice (Figure 5D, 5E), which likely indicates that, 
compared to host TF, tumor cell derived asTF is a more 
significant contributor to PDAC progression. Interestingly, 
RabMab1 suppressed the levels of M2 polarized TAMs in 
the tumors grown in TF-Low mice more potently than it 
did in TF-Het mice (Figure 5F); in agreement with that, 
E/N cadherin ratio was significantly increased in the 
tumors grown in TF-Low mice compared to the other two 
groups (Figure 5G). The levels of asTF protein expressed 
by tumor cells were not appreciably affected by RabMab1 
(data not shown).
DISCUSSION
In this study, we report the following set of 
findings: i) asTF-β1 integrin interactions render PDAC 
cells significantly more motile; ii) RabMab1-mediated 
targeting of asTF inhibits basal as well as asTF-potentiated 
migration of PDAC cells; iii) host flTF and/or asTF 
contributes to PDAC spread and influences the stromal 
Figure 4: Contribution of host-derived TF to tumor progression, orthotopically implanted Pt45.P1 cells. (A) Tumor 
progression was monitored via CVM-SapC-DOPS (n = 6). (B) Quantification of average primary tumor mass and (C) volume in each cohort 
(n = 6). (D) Quantification of spread to distal sites via CVM-SapC-DOPS imaging (analyzed areas were above and below the orange lines). 
(E) Eight view fields per specimen (n = 6 per specimen type) were assessed for vessel density, and (F) M2 polarized TAMs. (G) Representative 
images, Masson’s Trichrome stain (scale bar = 50 μm). (H) Quantification of percent area positive for Masson’s Trichrome stain.
Oncotarget25270www.impactjournals.com/oncotarget
composition of primary PDAC tumors; iv) tumor-derived 
asTF is cumulatively a more significant contributor to 
PDAC progression compared to host-TF.
Since the approval of gemcitabine in 1996, 
development of novel approaches to treat patients 
suffering from PDAC has remained stagnant. Over the 
last several years, different formulations and combinations 
of cytotoxic agents have improved the median survival 
rate by 4.4 months over gemcitabine monotherapy [19]. 
Despite these advances, there remains a severe need for 
new therapeutic modalities that can target host immunity, 
stromal microenvironment, and cancer cell signal 
transduction pathways [19]. In earlier studies, Rauch 
and colleagues reported that asTF is overexpressed in 
lung cancer and may thus contribute to its pathobiology 
[20, 21]; more recently, our groups demonstrated the 
potential for asTF to be a promising target in breast cancer 
[8]; in the present study, we show that inhibition of asTF-
integrin interactions holds much promise in stemming 
PDAC progression. asTF promotes migration of PDAC 
cells; we posit that asTF-β1 interactions may render PDAC 
cells more motile via asTF competing with laminin for β1 
integrin binding as well as promoting outside-in integrin 
signaling. It is also possible that, as we recently described 
in the breast cancer setting, asTF modulates binding and/
or migration on laminin, similarly to how flTF modulates 
migration on laminin [8]; an even more intriguing scenario 
might be envisioned whereby asTF competitively removes 
flTF-dependent inhibition of β1 integrins on laminin. We 
note that asTF binds to a distinct region of β1 integrins 
(residues 579–799) thereby promoting a conformational 
change in β1 integrins that renders them prone to 
activation by other external ligands [8]. Our asTF-specific 
inhibitory monoclonal antibody RabMab1 inhibits basal 
Figure 5: RabMab1 suppresses orthotopic growth of Pt45.P1 cells with equal efficacy, yet differentially affects the 
levels of tumor associated M2 polarized TAMs in TF-Het and TF-Low mice. (A) Average primary tumor mass, TF-Low and 
TF-Het SCID mice bearing orthotopic Pt45.P1 tumors (n ≥ 3). (B) Average primary tumor volume (n ≥ 3). (C) Western blot, phosphorylation 
of AKT (T308 & S473) in the three cohorts; each lane is a sample of an individual tumor. (D) Quantification of percent of Ki67+ nuclei, 
(E) vessel density, (F) levels of M2 polarized TAMs, and (G) E-cadherin/N-cadherin ratio in the tumors grown in the three cohorts; a 
minimum of eight view fields per each tumor (n ≥ 3 per specimen type) were counted and averaged. (RabMab1 = mAb).
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and asTF- potentiated PDAC cell migration. Here we 
show that, in addition to promoting tumor cell migration, 
asTF alters the tumor microenvironment by increasing 
the levels of M2 polarized TAMs, vessel density, and 
collagen deposition in the stroma. In the presence of 
RabMab1, Pt45.P1 cells grew significantly smaller tumors 
with fewer TAMs, blood vessels, and reduced collagen 
content; future studies will address whether systemic 
and continuous administration of RabMab1, as opposed 
to cancer cell co-implantation, will have a major impact 
on PDAC progression: given the hypovascular, scar-like 
structure of desmoplastic PDAC tumors, the ability of 
antibodies to penetrate solid tumors remains a concern. 
Currently, we are defining the protein domain(s) of human 
asTF critical to its binding to β1 integrins: molecular 
mapping of asTF-β1 integrin interactions will likely aid in 
the development of short inhibitory peptides and/or small-
molecule compounds with high tissue penetrance capacity. 
There is considerable interest in therapeutic targets 
that can attenuate aberrant signaling transduction pathways 
in PDAC. The PI3K/Akt pathway mediates a variety of 
cellular processes, such as cell proliferation, survival, 
and motility [22]. The PI3K/Akt pathway is activated in 
PDAC, and targeting the PI3K/Akt pathway can overcome 
resistance to apoptosis-inducing chemotherapy [23]. Our 
previous studies showed that asTF-integrin interactions 
promote AKT phosphorylation [7, 9]. RabMab1 inhibits 
phosphorylation of Akt at T308, which suggests that a 
reduction in tumor growth and spread may be in part 
due to the suppression of the Akt-dependent pro-survival 
pathways. Interestingly, we did not observe a change in 
the levels of pAkt-S473 post-treatment with RabMab1; 
the relative abundance of pAkt-S473 and pAkt-T308 is 
known to differ between various PDAC cell lines [24] 
yet no definitive information is available as to the relative 
importance of either site in PDAC pathobiology. Still, a 
recent study examining the pAkt-S473/pAkt-T308 status 
demonstrated that, compared to pAkt-S473, enhanced 
phosphorylation of pAkt-T308 as a more reliable biomarker 
for the progression of head-and-neck small cell carcinoma 
induced by smoking and/or excessive alcohol consumption 
[25], the two well-established risk factors for PDAC [19]. 
Numerous in vivo studies and preclinical findings 
suggest that targeting macrophage recruitment, 
polarization and activation may also prove effective 
therapeutic strategies in PDAC and other solid 
malignancies [26]. In many forms of cancer, high densities 
of TAMs are associated with poor clinical outcomes 
[27]. Levels of M2-polarized TAMs expressing mannose 
receptor CD206 [28, 29], but not CD68, positively 
correlate with negative outcome. In addition to being 
a more selective TAM marker, CD206 is associated 
with immunosuppression and the release of a variety of 
tumor-promoting growth factors that correlate with poor 
prognosis [30, 31]. In our orthotopic PDAC mouse model, 
RabMab1 lowers the levels of stromal CD206+ TAMs and 
impedes systemic spread; we propose that amelioration 
of metastases may in part be due to a decrease in TAMs 
because M2 polarized TAMs are known to promote 
epithelial-mesenchymal transition of pancreatic cancer 
cells [28]. Of note, Pt45.P1 cells formed much larger 
tumors in nude mice compared to SCID mice and so it 
is reasonable to propose that genetic background likely 
affects tumor size as well as spread of pancreatic cancer 
cells in an orthotopic setting. Tumor cell TF-induced 
coagulation, which results in fibrin formation, may 
promote formation of pre-metastatic niches by rendering 
distal sites more receptive to tumor cell growth via the 
recruitment of CD11b+ monocytes/macrophages [32]. In 
that light, our findings shown in Figure 4 indicate that in 
PDAC, host TF (i.e. non-tumor cell associated TF) may 
contribute significantly to tumor spread, complementing 
the studies by Palumbo and colleagues who demonstrated 
that tumor cell associated TF contributes to metastatic 
seeding in vivo [33]. We note that our studies are also 
consistent with the findings of Yu and colleagues who 
showed that subcutaneous tumors formed in TF-Low mice 
have reduced vessel density which does not significantly 
affect primary tumor growth [15]; however, distal spread 
was not studied in their models. CD11b+ monocyte 
recruitment is mediated through the binding of CD11b 
to clot components and activated endothelium [34]; we 
note that asTF-integrin interactions on human as well as 
murine microvascular endothelial cells promote monocyte 
recruitment [11, 12]. 
PDAC is characterized by extensive desmoplasia 
and much of the primary tumor mass is comprised of 
(extra)cellular components other than cancer cells, some 
of which may serve as a source of host TF in the tumor 
microenvironment. The relative contribution of host vs 
tumor-derived TF to PDAC progression is unknown. In our 
study, severe depletion of host TF had no significant impact 
on primary tumor weight and/or volume; however, we did 
observe a significant decrease in vessel density and M2 
polarized TAMs in the tumors grown in TF-Low mice. Most 
strikingly, systemic spread was also dampened in TF-Low 
mice. Still, targeting of tumor-derived asTF had a much 
more significant effect on PDAC progression compared 
to lowering the levels of host TF. Our data strongly 
suggest that asTF likely acts as an important regulator 
of the inflammatory microenvironment, known to play 
an essential role in K-RAS driven progression of PDAC 
[35]. In our hands, Pt45.P1 cells exhibit low constitutive 
levels of asTF but cooperate with exogenous asTF and 
host TF in formation of pro-inflammatory, pro-metastatic, 
collagen-rich, and desmoplastic milieu. It is possible that 
in addition to cancer cells themselves, inflammatory cells, 
and blood vessels [9], asTF also regulates the activity of 
pancreatic stellate cells implicated in PDAC-related fibrosis 
[36]. Because fibrosis and inflammation are regarded as 
elements of therapeutic intractability/resistance of PDAC 
to cytotoxic and targeted therapies [37], our results suggest 
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that our anti-asTF monoclonal antibody RabMab1 could 
act as therapeutic sensitizer. 
Aside from improving PDAC treatment, it is also 
critical to identify reliable circulating biomarkers that can 
non-invasively determine whether surgical intervention 
is feasible (e.g. resectable/unresectable disease), or 
aid in patient stratification. Multiple studies show that 
increased levels of TF protein circulating in plasma e.g. 
microvesicle-associated flTF, asTF, and/or degraded flTF 
[38] are associated with an increased risk for thrombosis in 
patients with cancer [39]. However, it is unclear whether 
circulating “total TF” comprises a cancer biomarker with 
prognostic utility. Using our novel asTF-specific ELISA, 
we show here that asTF is detectable at high levels in the 
circulation of mice bearing orthotopic PDAC tumors. 
Importantly, reduction of tumor size by RabMab1 led to 
a 3-fold reduction of the circulating levels of asTF from 
600 pg/mL to ~200 pg/ml (Figure 3): last year, we reported 
that pre-operative circulating levels of asTF ≥ 200 pg/ml 
may help identify PDAC patients with a more aggressive 
disease [40]; thus, we plan to conduct a prospective study 
to determine whether measuring circulating asTF may also 
aid in detecting recurrence in PDAC.  
In sum, our findings show that asTF-β1 integrin 
interactions play a major role in pathobiology of PDAC, 
and that antibody-based targeting of asTF may thus 
comprise a novel strategy to stem PDAC progression. 
Because asTF is i) dispensable to normal blood clotting, ii) 
expressed at higher levels in malignant tissues, and iii) able 
to promote tumor progression, it may very well comprise 
the preferred TF isoform to target in a cancer setting. 
MATERIALS AND METHODS
Cell lines
Human PDAC cell line Pt45.P1 is classified as 
grade III, harbors K-RAS/p53/p16 mutations, and has 
been extensively characterized [41]/authenticated by 
short tandem repeat analysis (ATCC) [7]. A second, new 
cell line termed Pt45.P1/asTFi was generated by stably 
co-transfecting Pt45.P1 cells with i) linearized pTet-On 
Advanced vector, and ii) pTRE-Tight vector (both from 
Clontech) with a human asTF expression cassette cloned 
into the plasmid’s multiple cloning site. Fugene HD 
(Roche) was used to transfect the constructs; cells were 
maintained in G418 and seven G418-resistant clones were 
harvested, expanded, and the consistency of the levels 
of doxycycline (Dox)-inducible asTF mRNA/protein 
overexpression was verified before the clones were pooled 
(data not shown). Both cell lines were grown in DMEM 
(Cellgro) supplemented with 10% fetal bovine serum 
(HyClone), 100 IU/mL penicillin, 100 µg/mL streptomycin, 
and 0.25 µg/mL amphotericin at 37°C in a humidified 
incubator (5% CO2). Neither primary growth nor spread of 
Pt45.P1 cells was affected by Dox (data not shown).
In vivo studies 
All animal studies were carried out in compliance 
with the protocol approved by the Institutional Animal 
Care and Utilization Committee, University of Cincinnati. 
Pt45.P1/asTFi cells were implanted in the pancreata of 
5-week-old female nude athymic mice, (n = 5/cohort) 
(Harland Laboratories). Mice were subdivided into three 
cohorts: 1) animals that began receiving Dox (2 µg/mL in 
water/sucrose) on day 1 of the study (“Dox”), 2) day 25 of 
the study (“Late Dox”), and 3) sucrose water alone (“No 
Dox”) for 5 weeks. Pt45.P1 cells were implanted in the 
pancreata of nude mice with WT levels of murine TF, as 
well as mice rescued from embryonic lethality caused by 
deficiency of the murine TF gene (Cf3) with a human TF 
(hTF) mini-gene: rescued mice (mTF−/−, hTF+/−, hereafter 
TF-Low) express only ~1% of TF levels compared to 50% 
expressed by their heterozygous counterparts (mTF+/−/
hTF+/−, hereafter TF-Het), and were backcrossed into 
severe combined immunodeficiency (SCID) background 
(n = 6/cohort) [15, 16].
In vivo efficacy studies of RabMab1 were carried 
out as follows. Pt45.P1 cells were resuspended in PBS 
containing 100 µg of RabMab1 or rabbit IgG isotype 
control, and implanted in the pancreata of nude athymic/
TF-Low/Het mice. Tumor progression was monitored via 
SapC-DOPS imaging over 7 weeks or when otherwise 
specified as previously described (n = 8/cohort) [42]. In 
brief, a multispectral imaging system FX (Kodak) was 
used to visualize tumor growth and spread employing Cell-
Vue Maroon (CVM)-labeled, nanovesicle-coupled Saponin 
C protein fragment H2 (CVM-SapC[H2]-DOPS) injected 
via tail vein; this compound selectively binds to tumor 
cells as well as tumor vasculature enriched in externalized 
phosphatidylserine [42]. Quantification of tumor spread 
was analyzed with Carestream MI software, background 
fluorescence normalized to sham-operated mice, and 
fluorescence was converted to photons per second per 
mm2. At the end of the study animals were sacrificed, 
necropsy was performed, and tumors were harvested and 
processed for protein, RNA, and histological analysis. 
Quantitative RT-PCR
Total RNA was isolated from cells and tissue 
flash-frozen in LN2 using RNeasy kit (Qiagen) as per 
the manufacturer’s instructions; cDNA was synthesized 
using Transcriptor (Roche). Quantitative RT-PCR was 
performed using our validated TaqMan probe and 
primer sets for asTF and flTF [7]; GAPDH was used as a 
housekeeping gene. 
Western blotting
Cells were trypsinized, washed with PBS, and pelleted. 
Cell pellets were resuspended in PBS supplemented with 
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Protease Inhibitor I cocktail (Roche) and lysed in Laemmli 
buffer with 2-Mercaptoethanol. Samples were denatured 
at 95°C for 10 min, loaded on 12% polyacrylamide gels 
(Life Technologies) and transferred to PVDF membranes. 
Membranes were blocked overnight at 4°C and probed with 
primary and corresponding HRP-conjugated secondary 
(Invitrogen) antibodies. Blots were developed using 
LumiLight (Roche), and chemiluminescent bands were 
visualized with X-ray film. Anti-pAkt T308 (Cat. No. 13038), 
anti-pAkt S473 (Cat. No. 9271), anti-total Akt (Cat. No. 
9272), anti-total MAPK (Cat. No. 9102), and anti-pMAPK 
p42/44 (Cat. No. 9101) antibodies were from Cell Signaling.
Cell migration studies
Gap closure/scratch assay was performed in 
triplicates by seeding 12-well plates with Pt45.P1/asTFi 
cells at 1 × 105/well. Dox (final concentration: 2 µg/mL) 
was added to the medium to induce asTF a day before 
the scratch was made, and the expression levels of asTF 
were verified by Western blotting. After cells adhered and 
reached confluence, the wells of the plate were scratched 
at the center using a P200 pipet tip. The generated gaps 
were analyzed for closure at 0, 18, 24, and 48 hours. The 
results were quantified using Image J software (NIH) by 
measuring the area (in pixels) that remained unoccupied 
at each time point; the area at 0 hours was set to 100%. 
Transmigration assays were carried out using 
24- well plates and inserts with 8.0 µm diameter pores 
(BD Bioscience) pre-coated with 50 µg/mL laminin 
(Sigma-Aldrich Cat. No. L4544) in Hank’s Balanced Salt 
Solution (HBSS; Cellgro) for 1.5 hrs. Excess laminin 
was removed from the inserts, following which 7.5 × 104 
Pt45.P1/asTFi cells were pre-incubated with anti-asTF 
antibody RabMab1, anti-integrin β1 (R & D Systems), 
anti-integrin α6 (R & D Systems), or isotype control 
antibodies (Jackson ImmunoResearch) for 30 min, placed 
in the upper chamber and allowed to migrate for 5 hrs at 
37°C, 5% CO2 toward serum-containing medium in the 
lower chamber. Afterwards, the inserts were fixed in ice-
cold methanol and non-migrated Pt45.P1/asTFi cells were 
removed from the luminal side with a cotton swab. Inserts 
were excised, stained, and preserved with Vectashield 
containing DAPI (Vector Labs). Images were captured on 
fluorescent microscope Keyence BZ-9000 (BIOREVO) at 
20X; 6 representative fields per insert (n = 3 inserts per 
each experimental condition) were captured and results 
analyzed using Image J. 
ELISA
Platelet-poor murine plasma derived from arterial 
blood was assayed for asTF protein levels using our custom 
sandwich ELISA as described [43]; in brief, samples were 
placed in 96-well capture plates and incubated for 3 hours 
at RT. Wells were washed and probed with asTF-specific 
detection antibody (RabMab1) conjugated to HRP for 2 
hours at RT. TMB substrate was then added and plate was 
incubated in the dark for 60 minutes; reaction was stopped 
with sulfuric acid and the plate was read at 450 nm. Serial 
dilutions of recombinant asTF in mouse plasma were used 
to generate a concentration curve in each run.
Tissue harvesting and histological analyses
Harvested tumor specimens were fixed in formalin 
overnight prior to paraffin embedding. Paraffin-embedded 
tumors were sectioned (4 µm), baked for 1 hour at 63°C, 
and rehydrated. Sections were placed in Antigen Retrieval 
Citra Solution (BioGenex) for 20 minutes in a pre-heated 
steamer at 95°C; afterwards, slides were allowed to cool 
and rinsed in wash buffer (Dako). Slides were blocked for 
12 min with a blocking cocktail, washed, and incubated 
with the primary antibodies: rabbit polyclonal anti-CD31 
(Abcam) and anti-CD206 (Abcam); anti-β1 (R & D 
Systems), and anti-α6 (R & D Systems) were applied for 
3 hours, slides washed and incubated with appropriate 
secondary antibodies for 30 minutes and Vectashield/
DAPI. Ki67 staining was carried out as previously 
described [8]; staining for E-cadherin and N-cadherin was 
performed using rabbit monoclonal antibodies 24E10 and 
D4R1H, respectively (both from Cell Signaling); staining 
for fibrin(ogen) was carried out using rabbit polyclonal 
antibody A0080 (Dako) that was previously characterized 
and shown to recognize human and murine fibrin(ogen) 
[44]. To detect apoptosis, TUNEL was performed using 
ApopTag Peroxidase In Situ Apoptosis Detection kit 
(EMD Millipore Cat. No. S7100). Deparaffinized 
tissue sections were treated with proteinase K (Thermo 
Scientific Cat. No. 17916) 200 µg/mL for 15 min at RT, 
endogenous peroxidase quenched with 3.0% H2O2, stained 
as per the manufacturerʼs protocol and developed with 
DAB (DAKO). Images were captured using BZ-9000 
BIOREVO (Keyence) and analyzed using BZ-II analyzer 
and Image J. 
Statistics
Mean values were compared using Student’s t-test 
between two groups, and for multiple group comparisons 
one-way ANOVA was used; p < 0.05 was considered 
significant. For statistical analyses, equal variance test was 
run, and in the cases where it failed, One Way ANOVA on 
Ranks Test was run along with Dunn’s test for all pairwise 
comparisons. All statistical analyses were performed 
using SigmaPlot v12.5. Data are presented as the mean ± 
standard deviation. 
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